Bristol-Myers Squibb Awards “Golden Tickets” for LabCentral to Neutrolis, Remora Therapeutics
November 28 2017 - 6:59AM
Business Wire
Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an
innovative, shared laboratory space designed as a launchpad for
life-sciences and biotech startups, today announced that Neutrolis
and Remora Therapeutics are the winners of Bristol-Myers Squibb’s
2017 Golden Tickets for LabCentral. As a platinum sponsor of
LabCentral, Bristol-Myers Squibb can select up to two innovative
life-sciences and biotech startup companies per year of active
sponsorship for “Golden Tickets,” which underwrite the cost of one
lab bench for one year in LabCentral’s Kendall Square facility.
This press release features multimedia. View
the full release here:
http://www.businesswire.com/news/home/20171128005362/en/
“We are delighted to award Golden Tickets to Neutrolis and
Remora Therapeutics, two emerging, innovative companies with
significant scientific potential,” said Carl Decicco, Ph.D., Head
of Discovery at Bristol-Myers Squibb. “The winners align with our
commitment to enabling scientific innovation in our research areas
of focus. We look forward to seeing these promising companies
advance their research programs at LabCentral. Our sponsorship of
LabCentral has facilitated important collaborations between
Bristol-Myers Squibb researchers and the Cambridge community, as we
prepare for our research site opening in Cambridge next year.”
Neutrolis is a preclinical drug discovery company focused on
researching new potential treatment options for inflammatory
diseases where uncontrolled neutrophilic inflammation may be
implicated, such as lupus and sepsis. Neutrophils are the
predominant white blood cells present during acute inflammation.
When patients are unable to regulate this inflammatory process, it
can lead to worsening of disease. Using its proprietary genetic
technology platform, Neutrolis is developing therapeutics with the
goal of neutralizing excessive neutrophilic inflammation, as well
as companion diagnostics to identify patients who are most likely
to benefit from such therapeutics.
Remora Therapeutics is a preclinical-stage biotechnology company
focused on developing novel platelet-based cell therapies.
Platelets are best known for their role in blood clotting, but they
are also involved in the pathogenesis of many major human
diseases, including cancer and conditions of autoimmunity.
Remora’s proprietary technology is designed to engineer
platelets to fight disease, and improve the quality of life for
patients living with debilitating illness.
“Bristol-Myers Squibb’s first two Golden Ticket winners, PanTher
and Suono Bio, have each met important research milestones and have
been terrific contributors to the LabCentral community,” commented
LabCentral Cofounder and President Johannes Fruehauf, M.D., Ph.D.
“We are pleased to welcome Neutrolis and Remora Therapeutics –
impressive startups – and we expect that they will likewise thrive
here.”
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose
mission is to discover, develop and deliver innovative medicines
that help patients prevail over serious diseases. For more
information about Bristol-Myers Squibb, visit us
at BMS.com or follow us on LinkedIn, Twitter,
YouTube and Facebook.
About LabCentral (www.labcentral.org; twitter
@labcentral)
LabCentral is a first-of-its-kind shared laboratory workspace in
the heart of the Kendall Square, Cambridge, biotech innovation hub.
Designed as a launchpad for high-potential life-sciences and
biotech startups, it offers everything startups need to begin
laboratory operations on day one and move their science forward
faster and more cost-efficiently. This includes: fully permitted
laboratory and office space, first-class facility and
administrative support, skilled laboratory personnel, a
domain-relevant expert speaker series ‒ as well as the other
critical services and support. A private, nonprofit institution,
LabCentral’s first site opened in 2013, thanks to a capital grant
from the Massachusetts Life Sciences Center, with support from its
real-estate partner, MIT. Founding sponsors include Triumvirate
Environmental and Johnson & Johnson Innovation. To accommodate
demand for its growing startups, LabCentral, with support from
Pfizer, Inc., plans to open LabCentral 610 in December 2017. In
2018, LabCentral will have capacity to serve a total of ~450
scientists and entrepreneurs in about 70 companies across its
two-building campus.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171128005362/en/
Bristol-Myers SquibbMedia:Chrissy Trank,
609-252-5609christina.trank@bms.comorInvestors:Bill Szablewski,
609-252-5894william.szablewski@bms.comorLabCentralCaroline
Grossman, 781-771-5579cgrossman@labcentral.org
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Apr 2023 to Apr 2024